The application of aptamers in cancer research: An up-to-date review

Future Oncology

Volumn 9, Issue 3, 2013, Pages 369-376

  Hu, Meidi ^a   Zhang, Kunhe ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

aptamer; biomarker; cancer; molecular therapy

Indexed keywords

APTAMER; BIOLOGICAL MARKER; DENDRIMER; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GOLD NANOPARTICLE; LIGAND; NANOCARRIER; NANOMATERIAL; POLO LIKE KINASE 1; PROTEIN BCL 2; PROTEIN BCL XL; RNA; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN 165;

ANTIANGIOGENIC ACTIVITY; BINDING AFFINITY; BRAIN CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER THERAPY; CELL DEATH; CHEMICAL MODIFICATION; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; DNA MICROARRAY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ERYTHROCYTE MEMBRANE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MASS SPECTROMETRY; MOLECULAR IMAGING; MOLECULAR LIBRARY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; DRUG CARRIERS; HUMANS; NANOPARTICLES; NEOPLASMS; RNA, SMALL INTERFERING; SELEX APTAMER TECHNIQUE; TUMOR MARKERS, BIOLOGICAL;

EID: 84874885652     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.201     Document Type: Review

References (87)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144(5), 646-674 (2011
2. Printz C. Cancer prevention and early detection efforts continue to make strides. Cancer 117(20), 4574-4575 (2011
3. Krupp M, Maass T, Marquardt JU et al. The functional cancer map: A systems-level synopsis of genetic deregulation in cancer. BMC Med. Genomics 4, 53 (2011
4. Paterlini-Bréchot P. Organ-specific markers in circulating tumor cell screening: An early indicator of metastasis-capable malignancy. Future Oncol. 7(7), 849-871 (2011
5. Govindarajan A, Paty PB. Predictive markers of colorectal cancer liver metastases. Future Oncol. 7(2), 299-307 (2011
6. Guthrie JW, Hamula CL, Zhang H, Le XC. Assays for cytokines using aptamers. Methods 38, 324-330 (2006
7. Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W. Applications of aptamers in cancer cell biology. Anal. Chim. Acta 621(2), 101-108 (2008
8. Jing M, Bowser MT. Methods for measuring aptamer-protein equilibria: A review. Anal. Chim. Acta 686(1-2), 9-18 (2011
9. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249(4968), 505-510 (1990
10. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 346(6287), 818-822 (1990
11. Wang J, Li G. Aptamers against cell surface receptors: Selection, modification and application. Curr. Med. Chem. 18(27), 4107-4116 (2011
12. Shamah SM, Healy JM, Cload ST. Complex target SELEX. Acc. Chem. Res. 41(1), 130-138 (2008
13. Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W. Development of DNA aptamers using cell-SELEX. Nat. Protoc. 5(6), 1169-1185 (2010
14. Rialon KL, White RR. Aptamers: Potential applications to pancreatic cancer therapy. Anticancer Agents Med. Chem. 11(5), 434-441 (2011
15. Barbas AS, Mi J, Clary BM, White RR. Aptamer applications for targeted cancer therapy. Future Oncol. 6(7), 1117-1126 (2010
16. Barbas AS, White RR. The development and testing of aptamers for cancer. Curr. Opin. Investig. Drugs 10(6), 572-578 (2009
17. de Franciscis V, Esposito CL, Catuogno S, Cellai L, Cerchia L. Aptamers as innovative diagnostic and therapeutic agents in the central nervous system. CNS Neurol. Disord. Drug Targets 8(5), 393-401 (2009
18. Tombelli S, Minunni M, Mascini M. Analytical applications of aptamers. Biosens. Bioelectron. 20(12), 2424-2434 (2005
19. Gold L, Ayers D, Bertino J et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5(12), e15004 (2010
20. Wang HQ, Wu Z, Tang LJ, Yu RQ, Jiang JH. Fluorescence protection assay: A novel homogeneous assay platform toward development of aptamer sensors for protein detection. Nucleic Acids Res. 39(18), e122 (2011
21. O'Sullivan CK. Aptasensors-The future of biosensing? Anal. Bioanal. Chem. 372(1), 44-48 (2002
22. Ito Y. Design and synthesis of functional polymers by in vitro selection. Polym. Adv. Technol. 15, 3-14 (2004
23. Ostroff RM, Bigbee WL, Franklin W et al. Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5(12), e15003 (2010
24. Shangguan D, Li Y, Tang Z et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl Acad. Sci. USA 103(32), 11838-11843 (2006
25. Sefah K, Meng L, Lopez-Colon D, Jimenez E, Liu C, Tan W. DNA aptamers as molecular probes for colorectal cancer study. PLoS One 5(12), e14269 (2010
26. Dharmasiri U, Balamurugan S, Adams AA, Okagbare PI, Obubuafo A, Soper SA. Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device. Electrophoresis 30(18), 3289-3300 (2009
27. Morris KN, Jensen KB, Julin CM, Weil M, Gold L. High affinity ligands from in vitro selection: Complex targets. Proc. Natl Acad. Sci. USA 95(6), 2902-2907 (1998
28. Blank M, Weinschenk T, Priemer M, Schluesener H. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessles. J. Biol. Chem. 276(19), 16464-16468 (2001
29. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment. Proc. Natl Acad. Sci. USA 100(26), 15416-15421 (2003
30. Wang C, Zhang M, Yang G et al. Single-stranded DNA aptamers that bind differentiated but not parental cells: Subtractive systematic evolution of ligands by exponential enrichment. J. Biotechnol. 102(1), 15-22 (2003
31. Tang Z, Shangguan D, Wang K et al. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 79(13), 4900-4907 (2007
32. Sefah K, Tang Z, Shangguan D et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 23(2), 235-244 (2009
33. Shangguan D, Meng L, Cao ZC et al. Identification of liver cancer-specific aptamers using whole live cells. Anal. Chem. 80(3), 721-728 (2008
34. Chen HW, Medley CD, Sefah K et al. Molecular recognition of small-cell lung cancer cells using aptamers. Chem. Med. Chem. 3(6), 991-1001 (2008
35. Shangguan D, Cao ZC, Li Y, Tan W. Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin. Chem. 53(6), 1153-1158 (2007
36. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: Application in drug delivery. Trends Biotechnol. 26(8), 442-449 (2008
37. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim. Biophys. Acta 1815(1), 44-64 (2011
38. Mallikaratchy PR, Ruggiero A, Gardner JR et al. A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res. 39(6), 2458-2469 (2011
39. He Z, Yu W. Stable feature selection for biomarker discovery. Comput. Biol. Chem. 34(4), 215-225 (2010
40. Li Y, Liu B, Dillon ST et al. Identification of a novel potential biomarker in a model of hemorrhagic shock and valproic acid treatment. J. Surg. Res. 159(1), 474-481 (2010
41. Yang Y, Iyer LK, Adelstein SJ, Kassis AI. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLoS One 3(11), e3661 (2008
42. Beretta L. Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery. Cancer Lett. 286(1), 134-139 (2009
43. Ray P, Rialon-Guenara KL, Veras E, Sullenger BA, White RR. Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. Clin. Invest. 122(5), 1734-1741 (2012
44. Shangguan D, Cao Z, Meng L et al. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 7(5), 2133-2139 (2008
45. Mallikaratchy P, Tang Z, Kwame S, Meng L, Shangguan D, Tan W. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in burkitt's lymphoma cell. Mol. Cell. Proteomics 6(12), 2230-2238 (2007
46. Cibiel A, Pestourie C, Ducongé F. In vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imaging. Biochimie 94(7), 1595-1606 (2012
47. Wang RE, Wu H, Niu Y, Cai J. Improving the stability of aptamers by chemical modification. Curr. Med. Chem. 18(27), 4126-4138 (2011
48. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-Aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res. 64(21), 7668-7672 (2004
49. Tan W, Wang H, Chen Y et al. Molecular aptamers for drug delivery. Trends Biotechnol. 29(12), 634-640 (2011
50. Mao X, Phillips JA, Xu H, Tan W, Zeng L, Liu G. Aptamer-nanoparticle strip biosensor for rapid and sensitive detection of cancer cells. Anal. Chem. 81(24), 10013-10018 (2009
51. Famulok M, Mayer G. Chemical biology: Aptamers in nanoland. Nature 439(7077), 666-669 (2006
52. Herr JK, Smith JE, Medley CD, Shangguan D, Tan W. Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. Anal. Chem. 78(9), 2918-2924 (2006
53. Estévez MC, Huang YF, Kang H et al. Nanoparticle-Aptamer conjugates for cancer cell targeting and detection. Methods Mol. Biol. 624, 235-248 (2010
54. Phillips JA, Xu Y, Xia Z, Fan ZH, Tan W. Enrichment of cancer cells using aptamers immobilized on a microfluidic channel. Anal. Chem. 81(3), 1033-1039 (2009
55. Xu Y, Phillips JA, Yan J, Li Q, Fan ZH, Tan W. Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells. Anal. Chem. 81(7), 7436-7442 (2009
56. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9(7), 537-550 (2010
57. Zhang Y, Hong H, Cai W. Tumor-Targeted drug delivery with aptamers. Curr. Med. Chem. 18(27), 4185-4194 (2011
58. Huang J, Moore J, Soffer S et al. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J. Pediatr. Surg. 36(2), 357-361 (2001
59. Drolet DW, Nelson J, Tucker CE et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharmaceut. Res. 17(12) 1503-1510 (2000
60. Chakraborty C. Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing. Curr. Drug Targets 8(3), 469-482 (2007
61. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 34(10), e73 (2006
62. Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465(7295), 227-230 (2010
63. Thiel KW, Hernandez LI, Dassie JP et al. Delivery of chemo-sensitizing siRNAs to HER2+- breast cancer cells using RNA aptamers. Nucleic Acids Res. 40(13), 6319-6337 (2012
64. Dassie JP, Liu XY, Thomas GS et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27(9), 839-849 (2009
65. Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Targets 8(7), 554-565 (2008
66. Kawala E, Ashihara E, Nakaoawa Y et al. A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro. Cancer Lett. 294(2), 245-253 (2010
67. Kanwar JR, Mahidhara G, Kanwar RK. Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discov. Today 16 (5-6), 188-202 (2011
68. Kanwar JR, Roy K, Kanwar RK. Chimeric aptamers in cancer cell-Targeted drug delivery. Crit. Rev. Biochem. Mol. Biol. 46(6), 459-477 (2011
69. Kim E, Jung Y, Choi H et al. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 31(16), 4592-4599 (2010
70. Lee IH, An S, Yu MK, Kwon HK, Im SH, Jon S. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J. Control. Release 155(3), 435-441 (2011
71. Hong H, Goel S, Zhang Y, Cai W. Molecular imaging with nucleic acid aptamers. Curr. Med. Chem. 18(27), 4195-4205 (2011
72. Rockey WM, Huang L, Kloepping KC, Baumhover NJ, Giangrande PH. Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg. Med. Chem. 19(13), 4080-4090 (2011
73. Xing H, Wong NY, Xiang Y, Lu Y. DNA aptamer functionalized nanomaterials for intracellular analysis, cancer cell imaging and drug delivery. Curr. Opin. Chem. Biol. 16(3-4), 429-435 (2012
74. Kim D, Jeong YY, Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4(7), 3689-3696 (2010
75. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62(14), 4029-4033 (2002
76. Zhou C, Jiang Y, Hou S, Ma B, Fang X, Li M. Detection of oncoprotein platelet-derived growth factor using a fluorescent signaling complex of an aptamer and TOTO. Anal. Bioanal. Chem. 384(5), 1175-1180 (2006
77. Green LS, Jellinek D, Bell C et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem. Biol. 2(10), 683-695 (1995
78. Ikebukuro K, Haseagwa H, Sode K. Selection and characterization of DNA aptamers against VEGF165 with aptamer blotting method and its application. Nucleic Acids Symp. Ser. (Oxf.) (51), 399-400 (2007
79. Li Y, Lee HJ, Corn RM. Detection of protein biomarkers using RNA aptamer microarrays and enzymatically amplified SPR imaging. Anal. Chem. 79(3), 1082-1088 (2007
80. Ferreira CS, Papamichael K, Guilbault G, Schwarzacher T, Gariepy J, Missailidis S. DNA aptamers against the MUC1 tumour marker: Design of aptamer-Antibody sandwich ELISA for the early diagnosis of epithelial tumours. Anal. Bioanal. Chem. 390(4), 1039-1050 (2008
81. Hicke BJ, Marion C, Chang Y et al. Tenascin-C Aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 276(52), 48644-48654 (2001
82. Golden MC, Collins BD, Willis MC, Koch TH. Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. J. Biotechnol. 81(2-3), 167-178 (2000
83. Cerchia L, Ducongé F, Pestourie C et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol. 3(4), e123 (2005
84. Huang YZ, Hernandez FJ, Gu B et al. RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol. Pharmacol. 82(4), 623-635 (2012
85. Cerchia L, Esposito CL, Camorani S et al. Targeting Axl with an high-Affinity inhibitory aptamer. Mol. Ther. 20(12), 2291-2303 (2012
86. Li N, Nguyen HH, Byrom M, Ellington AD. Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One 6(6), e20299 (2011
87. Kim MY, Jeong S. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther. 21(3), 173-178 (2011